peer_hh (@hh_peer) 's Twitter Profile
peer_hh

@hh_peer

Cardio-Nerd

ID: 1242400065701974016

calendar_today24-03-2020 10:37:25

136 Tweet

38 Takipçi

92 Takip Edilen

peer_hh (@hh_peer) 's Twitter Profile Photo

#ESCCongress Heart failure update 2023: As expected: new Class IA recommendation for SGLT2 Inhibitors in HFpEF and HFmrEF

#ESCCongress Heart failure update 2023: As expected: new Class IA recommendation for SGLT2 Inhibitors in HFpEF and HFmrEF
peer_hh (@hh_peer) 's Twitter Profile Photo

#ESCCongress Endocarditis guidelines 2023: on first sight, i see a lot of new recommendations for cefazolin (and maybe a little less gentamycin), great! In staph aureus (MSSA) endocarditis:Fluclox and Cefazolin both Class Ib. If beta-lactam allergy: cefazolin only. Annette Hennigs

#ESCCongress Endocarditis guidelines 2023: on first sight, i see a lot of new recommendations for cefazolin (and maybe a little less gentamycin), great! In staph aureus (MSSA) endocarditis:Fluclox and Cefazolin both Class Ib. If beta-lactam allergy: cefazolin only. <a href="/ABStewardess/">Annette Hennigs</a>
peer_hh (@hh_peer) 's Twitter Profile Photo

Endocarditis guideline 2023: If I got this long recommendation right: empiric treatment of native valve endocarditis is now eiter ampicillin+ceftriaxone or ampicillin+flucloxacillin+gentamycin. Next nail in the coffin of genta in endocarditis? #ESCCongress

Endocarditis guideline 2023: 
If I got this long recommendation right:  empiric treatment of native valve endocarditis is now eiter ampicillin+ceftriaxone or ampicillin+flucloxacillin+gentamycin. Next nail in the coffin of genta in endocarditis? 
#ESCCongress
peer_hh (@hh_peer) 's Twitter Profile Photo

ECMO in cardiogenic shock due to myocardial infarction: no survival benefit in the ECLS shock trial 🙁. Again a super relevant trial by Holger Thiele from Leipzig. #ESC2023 nejm.org/doi/full/10.10…

peer_hh (@hh_peer) 's Twitter Profile Photo

Super Besprechung der neuen Endokarditis-Leitlinie aus infektiologischer Sicht. Wer die Empfehlungen zur kalkulierten Therapie bei (noch) unbekanntem Erreger auch merkwürdig findet, bekommt hier eine Einordnung. Spoiler: es bleibt merkwürdig 😉

peer_hh (@hh_peer) 's Twitter Profile Photo

Numbers I'd like to memorize before doing the next screening TOE for endocarditis in staph aureus bacteremia: A priori risk of endocarditis: All patients: ca 10-20% Pat with cardiac device or prosthetic valve: ca 25-40% nosocomial SA infection: ca 5-10% #echofirst

peer_hh (@hh_peer) 's Twitter Profile Photo

PCI works in stable CAD as a symptomatic treatment. Puh.. 😅 Orbita 2 study with an outstanding design: the control group underwent a sham procedure as placebo! nejm.org/doi/full/10.10…

Deutsche Gesellschaft für Kardiologie (@dgk_org) 's Twitter Profile Photo

Der G-BA hat die Aufnahme der Computertomografie-Koronarangiografie #CCTA in den #GKV Leistungskatalog einstimmig beschlossen. #DGK-Präsident Holger Thiele sich im Video-Interview zur möglichen Rolle der Kardiologie und zu potenziellen Fallstricken. herzmedizin.de/fuer-aerzte-un…

Cardiac Trials (@cardiactrials) 's Twitter Profile Photo

Reminder - Anticoagulate atrial fibrillation regardless of chadsvasc score in: 1️⃣ hypertrophic cardiomyopathy 2️⃣ cardiac amyloid 3️⃣ prosthetic valve Stroke risk stratification scores like chadsvasc are meaningless in the face of these 3 ☝️

peer_hh (@hh_peer) 's Twitter Profile Photo

Echo made easy: to sort out high grade aortic stenosis, it‘s the gradient that matters. (instead of difficult equations)

peer_hh (@hh_peer) 's Twitter Profile Photo

Übervolle Session zum kardiogenen Schock #DGKJT2024: ECLS-Guru Benedikt Schrage aus Hamburg diskutiert, welche Patienten nach ECLS-Schock von einer ECMO profitieren könnten. Erhöhtes Lactat >5 als Kriterium? LV-Unloading als Schlüssel zum Erfolg? Karsten Schenke 📯 @kaschenke.blsky.social Michael Klinkhammer

Übervolle Session zum kardiogenen Schock #DGKJT2024: 
ECLS-Guru <a href="/BenediktSchrage/">Benedikt Schrage</a> aus Hamburg diskutiert, welche Patienten nach ECLS-Schock von einer ECMO profitieren könnten. 
Erhöhtes Lactat &gt;5 als Kriterium?
LV-Unloading als Schlüssel zum Erfolg?
<a href="/kaschenke/">Karsten Schenke 📯 @kaschenke.blsky.social</a> <a href="/klinki_hh/">Michael Klinkhammer</a>
peer_hh (@hh_peer) 's Twitter Profile Photo

Case Präsentation bei der AGIK #dgkjt2024 von Dimitrios Siamkouris: Burr Entrapment während Rotablation erfolgreich mittels Ping Pong Technik behandelt. Beim Rückzug dann erstaunlich viel Material mit herausgezogen.

Case Präsentation bei  der <a href="/AGIKinterv/">AGIK</a>  #dgkjt2024 von Dimitrios Siamkouris:

Burr Entrapment während Rotablation erfolgreich mittels Ping Pong Technik behandelt. Beim Rückzug dann erstaunlich viel Material mit herausgezogen.
Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

In EMPACT-MI, a randomized trial involving 6522 patients post-acute myocardial infarction, empagliflozin did not significantly reduce the combined outcome of heart failure hospitalization or death compared to placebo over a period of 17.9 months. Once again, a drug that

In EMPACT-MI, a randomized trial involving 6522 patients post-acute myocardial infarction, empagliflozin did not significantly reduce the combined outcome of heart failure hospitalization or death compared to placebo over a period of 17.9 months.  

Once again, a drug that
peer_hh (@hh_peer) 's Twitter Profile Photo

Nach vielen Rückschlägen bei Studien zur ECLS jetzt der erste positive Trial: In DanGer Shock konnte die Impella bei infarktbedingtem kardiogenen Schock die Mortalität reduzieren. Jetzt wird es spannend.

peer_hh (@hh_peer) 's Twitter Profile Photo

Das Konzept „Plaque sealing“ funktioniert! PREVENT Trial: Stenosen ohne Flusslimitierung (FFR negativ) wurden mit intravaskulärem Imaging untersucht und „vulnerable Plaques“ identifiziert. ➡️PCI dieser Läsionen führt zu besserem Outcome! Wichtige, alltagsrelevante Daten! 👍

Kardioklick (@kardioklick) 's Twitter Profile Photo

It's a shame that I can't seem to remember everything all the time. In an effort to keep this fact in mind, here's a short educational thread on RR-intervalls in Type I 2nd degree AV-Block (in Germany we like to call it Wenckebach). 1/

It's a shame that I can't seem to remember everything all the time. In an effort to keep this fact in mind, here's a short educational thread on RR-intervalls in Type I 2nd degree AV-Block (in Germany we like to call it Wenckebach).  1/
Gregg W. Stone MD (@greggwstone) 's Twitter Profile Photo

Our JACC editorial on the RESHAPE-HF2 trial: M-TEER in FMR-Erasing all doubt. RHF2 pts had lower EROA and ↑ LVEDV c/w COAPT (i.e. mostly mod FMR), w/substantially lower rates of mortality and HFH at 2 years. Nonetheless, HFH was markedly reduced and QOL was improved w/MitraClip.

Our JACC editorial on the RESHAPE-HF2 trial: M-TEER in FMR-Erasing all doubt. RHF2 pts had lower EROA and ↑ LVEDV c/w COAPT (i.e. mostly mod FMR), w/substantially lower rates of mortality and HFH at 2 years. Nonetheless, HFH was markedly reduced and QOL was improved w/MitraClip.
Henry Han (@hancardiomd) 's Twitter Profile Photo

Beta-Blockers for Secondary Prevention following #MI in Patients Without Reduced Ejection Fraction or #HeartFailure: An Updated Meta-Analysis Meta-analysis of 24 studies (290,349 patients) shows: 📍No significant mortality reduction in patients post-2010 with preserved EF (HR,

Beta-Blockers for Secondary Prevention following #MI in Patients Without Reduced Ejection Fraction or #HeartFailure: An Updated Meta-Analysis

Meta-analysis of 24 studies (290,349 patients) shows:

📍No significant mortality reduction in patients post-2010 with preserved EF (HR,